xofigo
NICE rejects Lilly lung cancer drug, recommends Bayer’s Xofigo and Amgen’s Imlygic
September 30, 2016Medical Communications, Sales and Marketing Imlygic, NICE, Portrazza, xofigo
The National Institute of Health and Care Excellence has issued final guidance rejecting Eli Lilly’s Portrazza (necitumumab) for the treatment …
NICE recommends Bayer’s Xofigo for prostate cancer treatment
September 2, 2016Medical Communications, Sales and Marketing Bayer, NICE, approval, prostate cancer, recommendation, xofigo
NICE has issued final draft guidance recommending Bayer’s Xofigo (radium-223 dichloride) for the treatment of prostate cancer. Previously, the drug …
NICE issues guidance for two prostate cancer drugs
June 5, 2015Sales and Marketing Bayer, Ferring, NICE, firmagon, xofigo
NICE has published draft guidance for two prostate cancer drugs, recommending a Bayer medicine but rejecting one from Ferring Pharmaceuticals. …
New drugs give Bayer record sales
February 26, 2015Sales and Marketing Bayer, Eylea, Radium-223 chloride, Stivarga, Xarelto, adempas, aflibercept, dekkers, german, regorafenib, riociguat, xofigo
Bayer has reported strong financial results for 2014 driven primary by sales of new medicines, although controversy surrounding its anti-clotting …
NICE backs Pfizer’s drug for advanced kidney cancer
December 16, 2014Sales and Marketing NICE, Pfizer, Sutent, Votrient, Zytiga, axitinib, inlyta, xofigo
UK healthcare guidance body NICE has issued final draft guidance recommending Pfizer’s Inlyta for advanced kidney cancer. The draft recommendation …
NICE says ‘no’ to Xofigo
March 24, 2014Sales and Marketing Bayer, CDF, NHS, NICE, abiraterone, prostate, xofigo
NICE has dealt Bayer a severe blow by not approving prostate cancer drug Xofigo for use on the NHS in …
Xarelto lift for Bayer
March 3, 2014Manufacturing and Production, Sales and Marketing Bayer, Eylea, Stivarga, Xarelto, blood thinner, xofigo
Bayer Group says sales of its blood thinner Xarelto will be higher than it had predicted, with peak annual sales …
Three new entries to Cancer Drugs Fund
February 5, 2014Research and Development, Sales and Marketing CDF, Kadcyla, NHS, Tafinlar, UK, xofigo
Three drugs – Roche’s Kadcyla, Bayer’s Xofigo and GlaxoSmithKline’s Tafinlar – have been added to England’s Cancer Drugs Fund (CDF). …
Bayer in $2.9 billion Algeta deal
December 19, 2013Sales and Marketing Algeta, Bayer, oncology, xofigo
Bayer and Algeta have decided to avoid the usual M&A dance, opting instead to agree a business deal with little …
Bayer targets Norway’s Algeta
November 27, 2013Sales and Marketing Algeta, Bayer, oncology, xofigo
Bayer HealthCare is in the market to buy Norwegian oncology specialist Algeta. The German pharma group has made a bid …
Bayer cancer drug gets EU approval
November 18, 2013Sales and Marketing Bayer, CHMP, EU, Xtandi, Zytiga, xofigo
Bayer’s prostate cancer treatment Xofigo has been shown the green light by the European Commission. Xofigo (radium Ra 223 dichloride) …
Latest content
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care
